{
    "ticker": "OTIC",
    "name": "Otonomy, Inc.",
    "description": "Otonomy, Inc. is a clinical-stage biotechnology company focused on developing innovative therapeutics for neurotology and other ear-related disorders. Founded in 2011 and headquartered in San Diego, California, Otonomy is dedicated to addressing significant unmet medical needs in the field of ear diseases. The company has developed a proprietary drug delivery platform designed to provide sustained release of medications directly to the inner ear, which is critical for treating conditions such as hearing loss and tinnitus. Otonomy's lead product candidate, OTO-313, is currently being evaluated in clinical trials for the treatment of tinnitus, a condition that affects millions of people worldwide. In addition to OTO-313, the company has several other product candidates in various stages of development, including OTO-104 for the prevention of cisplatin-induced hearing loss. Otonomy's mission is to improve the quality of life for patients suffering from ear disorders through groundbreaking therapies that can lead to better outcomes and enhanced patient care. With a commitment to innovation and a strong pipeline of product candidates, Otonomy is poised to become a leader in the field of otology.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "San Diego, California, USA",
    "founded": "2011",
    "website": "https://www.otonomy.com",
    "ceo": "David A. Weber, Ph.D.",
    "social_media": {
        "twitter": "https://twitter.com/otonomy",
        "linkedin": "https://www.linkedin.com/company/otonomy/"
    },
    "investor_relations": "https://investors.otonomy.com",
    "key_executives": [
        {
            "name": "David A. Weber, Ph.D.",
            "position": "CEO"
        },
        {
            "name": "Cynthia A. Smith",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "OTO-313",
                "OTO-104"
            ]
        }
    ],
    "seo": {
        "meta_title": "Otonomy, Inc. | Innovating Ear Therapeutics",
        "meta_description": "Explore Otonomy, Inc., a leader in developing groundbreaking therapeutics for ear disorders. Discover our commitment to improving patient outcomes in neurotology.",
        "keywords": [
            "Otonomy",
            "Biotechnology",
            "Ear Disorders",
            "Tinnitus Treatment",
            "Hearing Loss",
            "Neurotology"
        ]
    },
    "faq": [
        {
            "question": "What is Otonomy known for?",
            "answer": "Otonomy is known for developing innovative therapeutics for ear disorders, particularly tinnitus and hearing loss."
        },
        {
            "question": "Who is the CEO of Otonomy?",
            "answer": "David A. Weber, Ph.D. is the CEO of Otonomy, Inc."
        },
        {
            "question": "Where is Otonomy headquartered?",
            "answer": "Otonomy is headquartered in San Diego, California, USA."
        },
        {
            "question": "What are Otonomy's main products?",
            "answer": "Otonomy's main products include OTO-313 and OTO-104."
        },
        {
            "question": "When was Otonomy founded?",
            "answer": "Otonomy was founded in 2011."
        }
    ],
    "competitors": [
        "EARS",
        "HGEN",
        "AVEO"
    ],
    "related_stocks": [
        "AMGN",
        "REGN",
        "GILD",
        "INCY"
    ]
}